There are currently 140 active clinical trials seeking participants for Major Depressive Disorder research studies. The states with the highest number of trials for Major Depressive Disorder participants are California, Florida, Texas and New York.
Behavioral and Electrophysiological Effects of Ketamine in Treatment-Resistant Depression
NCT04239963
Recruiting
The overarching goal of the present study is to evaluate the effect of a subanesthetic dose of ketamine 24-hour post-injection on resting state functional connectivity, cognitive control, and reward learning.
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
03/11/2024
Locations: McLean Hospital, Belmont, Massachusetts
Conditions: Major Depressive Disorder
Register for Updates
Open-Label of SPN-820 in Adults With Major Depressive Disorder
NCT06235905
Recruiting
This study will evaluate the efficacy and safety of SPN-820 in Adults With Major Depressive Disorder (MDD)
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
03/06/2024
Locations: Muhammad Saleem Ismail, Rochester, New York
Conditions: Major Depressive Disorder
Register for Updates
Pain and Major Depressive Disorder
NCT04556890
Recruiting
This study will examine the effects of brain stimulation on pain symptoms associated with Major depressive disorder. This study will enroll 54 Subjects. Study subjects will be asked to complete surveys about their mood and well-being, 2 blood draws, 2 MRIs, 3 electroencephalograms, and receive 30 treatments of blinded transcranial magnetic stimulation. There is no control group as all subjects will receive some form of active treatment. Subjects are required to participate in 30-33 study visits... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
03/04/2024
Locations: UCLA Semel Institute, Los Angeles, California
Conditions: Major Depressive Disorder, Chronic Pain
Register for Updates
5-HTP and Creatine for Depression R33 Phase
NCT05895747
Recruiting
This is a three-armed clinical trial examining the effect of 5-hydroxytryptophan and creatine monohydrate as augmenting agents for the treatment of depression. Subjects will be randomized between 5-HTP 100mg BID + creatine 5g daily, 5-HTP 200mg BID + creatine 10g daily, vs double placebo, for 8 weeks. The ability of the interventions to affect biomarkers associated with depression will be assessed using brain phosphorus magnetic resonance spectroscopy, functional connectivity imaging, and plasma... Read More
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
03/02/2024
Locations: University of Utah Department of Psychiatry, Salt Lake City, Utah
Conditions: Major Depressive Disorder
Register for Updates
Psilocybin in Co-occuring Major Depressive Disorder and Borderline Personality Disorder
NCT05399498
Recruiting
The primary objective of the study is to evaluate the safety and efficacy of psilocybin in adults with major depressive disorder (MDD) and borderline personality disorder (BPD).
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
02/29/2024
Locations: University of Chicago, Chicago, Illinois
Conditions: Borderline Personality Disorder, Major Depressive Disorder
Register for Updates
Frequency and E-field Enhancement of ITBS for Depression (FREED)
NCT06003309
Recruiting
The investigators propose a randomized 3-arm double-blinded parallel experimental trial (20 sessions over 4 weeks) in 75 patients with TRD. The three arms include (1) the combination of a fully Individualized form of intermittent Theta Burst Stimulation (iTBS) (using BOTH the frequency and electric field (E-field) targeting approaches) (Ind-iTBS)), (2) iTBS individualized using E-field targeting only (targeted-iTBS) and (3) Standard iTBS treatment (i.e., typical iTBS localized to the dorsolatera... Read More
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
02/28/2024
Locations: University of California, San Diego, La Jolla, California +1 locations
Conditions: Major Depressive Disorder
Register for Updates
Concurrent fMRI-guided rTMS and Cognitive Therapy for the Treatment of Major Depressive Episodes
NCT03289923
Recruiting
Background: Repetitive transcranial magnetic stimulation (rTMS) is a treatment for depression. It stimulates the brain. Researchers want to see if using magnetic resonance imaging (MRI) scans helps locate the best area for rTMS in each person. They also want to find other ways to make it more effective. Objective: To study the effects of combining MRI- guided transcranial magnetic stimulation (TMS) and talk therapy on the brain in people with depression. Eligibility: Adults ages 18-75 with... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
02/28/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Major Depressive Disorder
Register for Updates
Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2) in Major Depressive Disorder (MDD)
NCT05757791
Recruiting
The primary purpose of this study is to determine whether empagliflozin, a medication in a class known as sodium-glucose cotransporter-2 inhibitors (SGLT2) inhibitors, may reduce symptoms of depression. Since this medication helps the body make metabolites known as ketone bodies which can serve as an alternate energy source for the brain, the investigators can also test whether ketone bodies help with depressed mood.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
02/26/2024
Locations: NYU Langone Health, New York, New York
Conditions: Major Depressive Disorder
Register for Updates
Low-Intensity Focused Ultrasound for Treatment-Resistant Depression
NCT06013384
Recruiting
The Investigators are proposing to demonstrate safety and efficacy of LIFUP for treatment resistant major depressive disorder in a ten-patient pilot study. LIFUP is an emerging treatment with the advantage of being able to target subcortical transcranial targets, which may have superior efficacy or a shorter treatment course compared to other available treatments such as transcranial magnetic stimulation. This study will investigate the effect of this stimulation on the left subgenual cingulate... Read More
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
02/16/2024
Locations: 30 Bee Street, Charleston, South Carolina
Conditions: Major Depressive Disorder, Treatment Resistant Depression
Register for Updates
Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans
NCT04032301
Recruiting
Co-occurring post-traumatic stress disorder (PTSD) and major depressive disorder (MDD) is the most common response to trauma; it is associated with poor clinical outcomes and substantial human disability. Veterans with both PTSD and MDD (PTSD+MDD) have been shown to be at much greater suicidal risk than individuals with only one of these disorders. Ketamine given as repeated infusions has been shown to be effective in rapidly reducing PTSD and MDD symptoms in treatment resistant PTSD+MDD individ... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
02/16/2024
Locations: Minneapolis Veterans Affairs Health Care System, Minneapolis, Minnesota
Conditions: Post-Traumatic Stress Disorders, Major Depressive Disorder
Register for Updates
A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD)
NCT04855747
Recruiting
This is an outpatient, 2-arm, Phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of REL-1017 once daily (QD) as an adjunctive treatment of Major Depressive Disorder. Study participants will continue to take their current antidepressant therapy in addition to the study drug or placebo for the duration of the treatment period.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
02/15/2024
Locations: Relmada Site, Saraland, Alabama +77 locations
Conditions: Major Depressive Disorder, Depression
Register for Updates
Open Label Optimization Study
NCT05819021
Recruiting
The goal of this observational study is to demonstrate effectiveness in the treatment of Major Depressive Disorder The primary objective is to assess the effectiveness in the treatment of Major Depressive Disorder using the CGI-I at the end of the treatment Participants will receive 10 treatments per day for 5 days (M-F) of SAINT®
Gender:
All
Ages:
18 years and above
Trial Updated:
02/15/2024
Locations: BrainHealth Solutions, Costa Mesa, California +6 locations
Conditions: Major Depressive Disorder
Register for Updates